June 24, 2022 06:07 AM EDTUpdated 08:37 AM
Peer Review

Af­ter sev­en months of search­ing, Lan­dos hires a CEO; Mar­ty Du­vall re-emerges from ill-fat­ed On­copep­tides tenure

Alex Hoffman

Copy Chief

Kathy Wong

Editor

Kyle LaHucik

Senior Reporter

Lan­dos Bio­phar­ma has land­ed a new CEO af­ter sev­en months of be­ing led by an in­ter­im chief ex­ec­u­tive.

Gre­go­ry Oakes

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

A service from the Financial Times